257 related articles for article (PubMed ID: 11751441)
21. Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population.
Kiyohara C; Washio M; Horiuchi T; Tada Y; Asami T; Ide S; Takahashi H; Kobashi G;
Lupus; 2009 Jun; 18(7):630-8. PubMed ID: 19433464
[TBL] [Abstract][Full Text] [Related]
22. 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility.
Belogubova EV; Kuligina ESh; Togo AV; Karpova MB; Ulibina JM; Shutkin VA; Hanson KP; Popowski K; Mosyagin I; Cascorbi I; Hirvonen A; Imyanitov EN
Cancer Lett; 2005 Apr; 221(2):177-83. PubMed ID: 15808403
[TBL] [Abstract][Full Text] [Related]
23. NAT2, GSTM-1, cigarette smoking, and risk of colon cancer.
Slattery ML; Potter JD; Samowitz W; Bigler J; Caan B; Leppert M
Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1079-84. PubMed ID: 9865425
[TBL] [Abstract][Full Text] [Related]
24. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis.
Ambrosone CB; Kropp S; Yang J; Yao S; Shields PG; Chang-Claude J
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):15-26. PubMed ID: 18187392
[TBL] [Abstract][Full Text] [Related]
25. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study.
Peluso M; Airoldi L; Armelle M; Martone T; Coda R; Malaveille C; Giacomelli G; Terrone C; Casetta G; Vineis P
Cancer Epidemiol Biomarkers Prev; 1998 Apr; 7(4):341-6. PubMed ID: 9568791
[TBL] [Abstract][Full Text] [Related]
26. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.
Rouissi K; Ouerhani S; Marrakchi R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Cancer Genet Cytogenet; 2009 Apr; 190(2):101-7. PubMed ID: 19380028
[TBL] [Abstract][Full Text] [Related]
27. N-acetyltransferase 2, exposure to aromatic and heterocyclic amines, and receptor-defined breast cancer.
Rabstein S; Brüning T; Harth V; Fischer HP; Haas S; Weiss T; Spickenheuer A; Pierl C; Justenhoven C; Illig T; Vollmert C; Baisch C; Ko YD; Hamann U; Brauch H; Pesch B;
Eur J Cancer Prev; 2010 Mar; 19(2):100-9. PubMed ID: 19996973
[TBL] [Abstract][Full Text] [Related]
28. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Brockmöller J; Cascorbi I; Kerb R; Roots I
Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
[TBL] [Abstract][Full Text] [Related]
29. Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene.
Butkiewicz D; Popanda O; Risch A; Edler L; Dienemann H; Schulz V; Kayser K; Drings P; Bartsch H; Schmezer P
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2242-6. PubMed ID: 15598786
[TBL] [Abstract][Full Text] [Related]
30. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk.
Millikan RC; Pittman GS; Newman B; Tse CK; Selmin O; Rockhill B; Savitz D; Moorman PG; Bell DA
Cancer Epidemiol Biomarkers Prev; 1998 May; 7(5):371-8. PubMed ID: 9610785
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.
Salagovic J; Kalina I; Stubna J; Habalová V; Hrivnák M; Valanský L; Kohút A; Biros E
Neoplasma; 1998; 45(5):312-7. PubMed ID: 9921921
[TBL] [Abstract][Full Text] [Related]
32. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer.
Broberg K; Björk J; Paulsson K; Höglund M; Albin M
Carcinogenesis; 2005 Jul; 26(7):1263-71. PubMed ID: 15746160
[TBL] [Abstract][Full Text] [Related]
33. Nonsmoking-related arylamine exposure and bladder cancer risk.
Skipper PL; Tannenbaum SR; Ross RK; Yu MC
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):503-7. PubMed ID: 12814994
[TBL] [Abstract][Full Text] [Related]
34. Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma.
Betti M; Neri M; Ferrante D; Landi S; Biava A; Gemignani F; Bertolotti M; Mirabelli D; Padoan M; Ugolini D; Botta M; Bonassi S; Magnani C; Dianzani I
Int J Hyg Environ Health; 2009 May; 212(3):322-9. PubMed ID: 18838334
[TBL] [Abstract][Full Text] [Related]
35. Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe.
McKay JD; Hashibe M; Hung RJ; Wakefield J; Gaborieau V; Szeszenia-Dabrowska N; Zaridze D; Lissowska J; Rudnai P; Fabianova E; Mates D; Foretova L; Janout V; Bencko V; Chabrier A; Hall J; Boffetta P; Canzian F; Brennan P
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):141-7. PubMed ID: 18199719
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer.
Ochs-Balcom HM; Wiesner G; Elston RC
Am J Epidemiol; 2007 Aug; 166(3):246-54. PubMed ID: 17535831
[TBL] [Abstract][Full Text] [Related]
37. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.
Risch A; Wallace DM; Bathers S; Sim E
Hum Mol Genet; 1995 Feb; 4(2):231-6. PubMed ID: 7757072
[TBL] [Abstract][Full Text] [Related]
38. Tobacco use and occupational exposure to carcinogens, but not N-acetyltransferase 2 genotypes are major risk factors for bladder cancer in the Japanese.
Kontani K; Kawakami M; Nakajima T; Katsuyama T
Urol Res; 2001 Jun; 29(3):199-204. PubMed ID: 11482447
[TBL] [Abstract][Full Text] [Related]
39. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
[TBL] [Abstract][Full Text] [Related]
40. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
Moore LE; Baris DR; Figueroa JD; Garcia-Closas M; Karagas MR; Schwenn MR; Johnson AT; Lubin JH; Hein DW; Dagnall CL; Colt JS; Kida M; Jones MA; Schned AR; Cherala SS; Chanock SJ; Cantor KP; Silverman DT; Rothman N
Carcinogenesis; 2011 Feb; 32(2):182-9. PubMed ID: 21037224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
